Evaluating Perfusion-Guided Endovascular Treatment Versus Standard Care for Acute Ischemic Stroke Caused by Medium Vessel Occlusion Within 24 Hours

What this Trial Is About

Researchers are evaluating the safety and effectiveness of perfusion-guided endovascular treatment EVT compared to standard medical care for adults who have had an acute ischemic stroke caused by medium vessel occlusion within 24 hours of symptom onset. This study focuses on patients with specific artery blockages confirmed by imaging and a baseline stroke severity score of 8 or higher. The goal is to see how well patients recover by measuring their ability to function independently 90 days after treatment. Participants will be randomly assigned to one of two groups one receiving endovascular treatment plus best medical treatment, and the other receiving best medical treatment alone. The endovascular treatment involves techniques such as thrombectomy, thromboaspiration, intraarterial thrombolysis, balloon angioplasty, stenting, or combinations of these, performed immediately after randomization. Best medical treatment follows current clinical guidelines and is administered independently of the study treatment. During the study, participants will undergo neuroimaging to confirm eligibility and will be monitored regularly for neurological improvement, safety events, and overall recovery using scales like the modified Rankin Scale at 90 days and one year. Researchers will collect data on stroke severity, quality of life, bleeding complications, and mortality. The study starts in February 2026 and continues until September 2028, with participant follow-up lasting at least one year after treatment.

Advancing Reperfusion Therapy for Ischemic Stroke: Perfusion-guided Endovascular Intervention for Medium Vessel Occlusion Therapy